EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T-cell therapies to treat cancers, today announced that new clinical data from its first-in-human study of ET019003, an anti-CD19 T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL), will be presented in a poster session at the 61st American Society of Hematology (ASH) Annual Meeting on December 8, 2019. ET019003 is engineered by incorporating a co-stimulatory molecule into T-cells expressing an anti-CD19 antibody T-cell receptor (AbTCR) core structure, representing the next generation of Eureka’s novel T-cell therapy generated with the ARTEMIS™ T-cell platform.
“We are excited to be selected for poster presentation at the 2019 ASH Meeting,” said Dr. Cheng Liu, Founder & CEO of Eureka Therapeutics. “This is significant recognition of the progress we are making in the development of novel T cell therapies from our ARTEMIS™ platform, and we look forward to sharing additional updates from our additional programs at the conference.”
Details of the poster presentation are as follows:
Title: |
First-in-Human Study of ET019003, a Next Generation Anti-CD19 T-Cell Therapy, in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL) |
|
Publication: |
2870 |
|
Session: |
626 |
|
Date: |
Sunday, December 8, 2019 |
|
Time: |
6:00 - 8:00pm EST |
|
Location: |
Orange County Convention Center, Hall B |
|
Presenter: |
Pengcheng He, the First Affiliated Hospital of Xi’an Jiaotong University, China |
The ASH abstract is now available at www.hematology.org. The poster presentation will include additional data not available in the abstract.
ABOUT EUREKA THERAPEUTICS, INC.
Eureka Therapeutics, Inc. is a privately held clinical stage biotechnology company focused on developing novel T-cell therapies to treat cancers. Its core technology centers around its proprietary ARTEMIS™ antibody T-cell receptor (AbTCR) platform and E-ALPHA® antibody discovery platform for discovery and development of potentially safer and more effective T-cell therapies for treatment of multiple solid and hematologic tumors. ET140202, the Company’s lead asset, is currently in a Phase I/II US multicenter clinical trial in patients with advanced hepatocellular carcinoma (HCC).
Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area. For more information on the company, please visit www.eurekatherapeutics.com.
